BACKGROUND: Streptococcus pneumoniae is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. METHODS: In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. The primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or serotype 6A. RESULTS: From February 2003 through October 2007, we followed 496 patients (of whom 44% were male and 88% were HIV-seropositive) for 798 person-years of observation. There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infected subgroup. In 24 patients, there were 19 episodes that were caused by vaccine serotypes and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 occurred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after vaccination was significantly lower in the vaccine group than in the placebo group (3 vs. 17, P=0.002), and the number of minor adverse events was significantly higher in the vaccine group (41 vs. 13, P=0.003). CONCLUSIONS: The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current Controlled Trials number, ISRCTN54494731.) 2010 Massachusetts Medical Society
RCT Entities:
BACKGROUND:Streptococcus pneumoniae is a leading and serious coinfection in adults with humanimmunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine is suboptimal. Protein conjugate vaccines offer a further option for protection, but data on their clinical efficacy in adults are needed. METHODS: In this double-blind, randomized, placebo-controlled clinical efficacy trial, we studied the efficacy of a 7-valent conjugate pneumococcal vaccine in predominantly HIV-infected Malawian adolescents and adults who had recovered from documented invasive pneumococcal disease. Two doses of vaccine were given 4 weeks apart. The primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or serotype 6A. RESULTS: From February 2003 through October 2007, we followed 496 patients (of whom 44% were male and 88% were HIV-seropositive) for 798 person-years of observation. There were 67 episodes of pneumococcal disease in 52 patients, all in the HIV-infected subgroup. In 24 patients, there were 19 episodes that were caused by vaccine serotypes and 5 episodes that were caused by the 6A serotype. Of these episodes, 5 occurred in the vaccine group and 19 in the placebo group, for a vaccine efficacy of 74% (95% confidence interval [CI], 30 to 90). There were 73 deaths from any cause in the vaccine group and 63 in the placebo group (hazard ratio in the vaccine group, 1.18; 95% CI, 0.84 to 1.66). The number of serious adverse events within 14 days after vaccination was significantly lower in the vaccine group than in the placebo group (3 vs. 17, P=0.002), and the number of minor adverse events was significantly higher in the vaccine group (41 vs. 13, P=0.003). CONCLUSIONS: The 7-valent pneumococcal conjugate vaccine protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or serotype 6A. (Current Controlled Trials number, ISRCTN54494731.) 2010 Massachusetts Medical Society
Authors: S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards Journal: Pediatr Infect Dis J Date: 2000-03 Impact factor: 2.129
Authors: D R Feikin; C M Elie; M B Goetz; J L Lennox; G M Carlone; S Romero-Steiner; P F Holder; W A O'Brien; C G Whitney; J C Butler; R F Breiman Journal: Vaccine Date: 2001-11-12 Impact factor: 3.641
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham Journal: Lancet Date: 2003-08-02 Impact factor: 79.321
Authors: Stephen B Gordon; Mas Chaponda; Amanda L Walsh; Christopher J M Whitty; Melita A Gordon; C Edward Machili; Charles F Gilks; Martin J Boeree; Sam Kampondeni; Robert C Read; Malcolm E Molyneux Journal: AIDS Date: 2002-07-05 Impact factor: 4.177
Authors: Stephen B Gordon; Stonard Kanyanda; Amanda L Walsh; Kirsty Goddard; Mas Chaponda; Victoria Atkinson; Wakisa Mulwafu; Elizabeth M Molyneux; Ed E Zijlstra; Malcolm E Molyneux; Steve M Graham Journal: Emerg Infect Dis Date: 2003-06 Impact factor: 6.883
Authors: Hugues de Lavallade; Ahmad Khoder; Melanie Hart; Anushruti Sarvaria; Takuya Sekine; Abdullah Alsuliman; Stephan Mielke; Alexandra Bazeos; Kate Stringaris; Sara Ali; Dragana Milojkovic; Letizia Foroni; Aristeidis Chaidos; Nichola Cooper; Ian Gabriel; Jane Apperley; Sarah Belsey; Robert J Flanagan; John Goldman; Elizabeth J Shpall; Peter Kelleher; David Marin; Katayoun Rezvani Journal: Blood Date: 2013-05-29 Impact factor: 22.113
Authors: Lindsay K Nicholson; Harsh Pratap; Elisabeth Bowers; Elise Gunzburger; Srinivasa R Bandi; Edward M Gardner; Brent E Palmer; Timothy Wright; John Kittelson; Edward N Janoff Journal: Immunobiology Date: 2018-09-07 Impact factor: 3.144
Authors: C Rock; C Sadlier; J Fitzgerald; M Kelleher; C Dowling; S Kelly; C Bergin Journal: Eur J Clin Microbiol Infect Dis Date: 2013-03-24 Impact factor: 3.267